PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Moriarty, Patrick M.
TI  - Alirocumab Has Greater Reduction of LDL-C Than Ezetimibe in Patients with Statin Intolerance
DP  - 2014  01
TA  - MD Conference Express
PG  - 16--17
VI  - 14
IP  - 52
4099  - http://mdc.sagepub.com/content/14/52/16.short
4100  - http://mdc.sagepub.com/content/14/52/16.full
AB  - In clinical practice, up to 25% of patients are statin intolerant as a result of symptoms and abnormalities in biomarkers. This article discusses results from the Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular Risk, Who Are Intolerant to Statins [Odyssey Alternative; NCT01709513]. These trials compared statin intolerant patients who were treated with alirocumab versus ezetimibe.